Investigational drug · Phase 3
Atezolizumab followed by Atezolizumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
299
Any phase or sponsor naming "Atezolizumab followed by Atezolizumab"
First trial start
2026
Aug 4, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Atezolizumab followed by Atezolizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Cell Lung Cancer Extensive Stage
- Small-cell Lung Cancer
- Small Cell Carcinoma
- Sclc
- SCLC,Extensive Stage
- Lung Cancer
- Lung Cancer Metastatic
- Lung Cancer Stage IV
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Atezolizumab followed by Atezolizumab" as an intervention, largest first.
Groupe Hospitalier Pitie-SalpetriereAcademic, hospital or other
NCT04294771 · 500,000 participants (planned) · Start Jan 1, 2019 · Primary completion Jan 1, 2030
Drug: ICI · For: Myocarditis; Cardiomyopathies; Heart Diseases and 3 more
Sites: Paris, France
Groupe Hospitalier Pitie-SalpetriereAcademic, hospital or other
NCT05934214 · 141,630 participants · Start Jan 1, 2023 · Primary completion Dec 31, 2023
Drug: Immune checkpoint inhibitor · For: Cancer; Immune-related Adverse Event; Immune Checkpoint Inhibitor-Related Myocarditis
Sites: Paris, France · 2 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03782207 · 2,756 participants · Start Feb 7, 2019 · Primary completion Jul 31, 2026
Drug: Atezolizumab · For: Urothelial Carcinoma; Non-Small Cell Lung Cancer; Small Cell Lung Cancer and 1 more
Sites: Buenos Aires, Argentina; CABA, Argentina; Ciudad Autonoma Buenos Aires, Argentina · 257 sites in all
Johns Hopkins UniversityAcademic, hospital or other
NCT04898751 · 2,214 participants · Start Jan 1, 2008 · Primary completion Aug 31, 2020
Drug: Immune checkpoint inhibitor (ICI) · For: Cutaneous Toxicity From ICI Therapy
Sites: Baltimore, Maryland
- A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerPivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03498716 · 2,199 participants · Start Aug 2, 2018 · Primary completion Aug 14, 2023
Drug: Atezolizumab; Paclitaxel and 2 more · For: Triple Negative Breast Cancer
Sites: Concord, California; Los Angeles, California; St. Helena, California · 364 sites in all
- Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboPivotal-lookingActive, not recruiting
NSABP Foundation IncResearch network
NCT03281954 · 1,550 participants · Start Dec 19, 2017 · Primary completion Dec 31, 2024
Drug: Placebo; Atezolizumab · For: Triple Negative Breast Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Jonesboro, Arkansas · 217 sites in all
- A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03038100 · 1,301 participants · Start Mar 8, 2017 · Primary completion Feb 8, 2022
Drug: Paclitaxel; Carboplatin and 3 more · For: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 268 sites in all
- Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02486718 · 1,280 participants · Start Oct 31, 2015 · Primary completion Jan 26, 2024
Drug: Atezolizumab; Cisplatin and 4 more · For: Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Encinitas, California; Fountain Valley, California · 216 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02366143 · 1,202 participants · Start Mar 31, 2015 · Primary completion Sep 13, 2019
Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Bevacizumab and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Chandler, Arizona; Flagstaff, Arizona; Bellflower, California · 240 sites in all
- A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04873362 · 1,188 participants · Start May 4, 2021 · Primary completion Mar 31, 2027
Drug: Atezolizumab; Trastuzumab Emtansine and 2 more · For: Breast Cancer
Sites: Birmingham, Alabama; Buena, California; Santa Monica, California · 238 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Small Cell Lung Cancer Extensive Stage
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- GocatamigHPN328, MK-6070Phase 34 trials
Merck & Co. · Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer
- BL-M14D1Phase 32 trials
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- quaratusugene ozeplasmidREQORSAPhase 22 trials
Genprex, Inc. · Carcinoma, Non-Small Cell Lung, Small Cell Lung Cancer Extensive Stage
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.